Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.
Thromb Res
; 180: 37-42, 2019 Aug.
Article
en En
| MEDLINE
| ID: mdl-31200341
Texto completo:
1
Bases de datos:
MEDLINE
Métodos Terapéuticos y Terapias MTCI:
Terapias_biologicas
/
Aromoterapia
Asunto principal:
Piridinas
/
Tiazoles
/
Trombosis
/
Dalteparina
/
Inhibidores del Factor Xa
/
Rivaroxabán
/
Anticoagulantes
Tipo de estudio:
Etiology_studies
/
Guideline
/
Health_economic_evaluation
/
Prognostic_studies
/
Risk_factors_studies
/
Systematic_reviews
Idioma:
En
Revista:
Thromb Res
Año:
2019
Tipo del documento:
Article